Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Mieog, J Sven D ^a   de Kruijf, Esther M ^a   Bastiaannet, Esther ^a   Kuppen, Peter J K ^a   Sajet, Anita ^a   de Craen, Anton J M ^a   Smit, Vincent T H B M ^a   van de Velde, Cornelis J H ^a   Liefers, Gerrit Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age; ALDH1; Breast cancer; Prognostic factor part of this work has been presented at the american association for cancer research (AACR) annual meeting 2011

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ISOENZYME; RETINAL DEHYDROGENASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RESEARCH; CANCER STAGING; CANCER STEM CELL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; RISK FACTOR; SURVIVAL; TISSUE MICROARRAY; AGE; AGE DISTRIBUTION; BREAST TUMOR; EPIDEMIOLOGY; FEMALE; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MICROARRAY ANALYSIS; MIDDLE AGED; PROGNOSIS; RETINAL DEHYDROGENASE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856086583     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-42     Document Type: Article

References (26)

1. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol 2009, 36(3):237-249. 10.1053/j.seminoncol.2009.03.001, 2894028, 19460581.
2. Remvikos Y, Magdelenat H, Dutrillaux B. Genetic evolution of breast cancers. III: age-dependent variations in the correlations between biological indicators of prognosis. Breast Cancer Res Treat 1995, 34(1):25-33. 10.1007/BF00666488, 7749157.
3. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000, 92(7):550-556. 10.1093/jnci/92.7.550, 10749910.
4. Beadle BM, Woodward WA, Buchholz TA. The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol 2011, 21(1):26-34. 10.1016/j.semradonc.2010.09.001, 3041510, 21134651.
5. Anderson WF, Jatoi I, Sherman ME. Qualitative age interactions in breast cancer studies: mind the gap. J Clin Oncol 2009, 27(32):5308-5311. 10.1200/JCO.2009.22.9450, 2773215, 19826117.
6. Bastiaannet E, Liefers GJ, de Craen AJ, Kuppen PJ, van de Water W, Portielje JE, van der Geest LG, Janssen-Heijnen ML, Dekkers OM, van de Velde CJ, et al. Breast cancer in elderly compared to younger patients in The Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat 2010, 124(3):801-807. 10.1007/s10549-010-0898-8, 20428937.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
8. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, Purushotham AD. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008, 122(2):298-304. 10.1002/ijc.23103, 17935134.
9. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1(5):555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
10. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008, 10(1):R10. 10.1186/bcr1855, 2374965, 18241344.
11. Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010, 123(1):97-108. 10.1007/s10549-009-0619-3, 19911270.
12. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009, 15(12):4234-4241. 10.1158/1078-0432.CCR-08-1479, 19509181.
13. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98(24):1777-1785. 10.1093/jnci/djj495, 17179479.
14. Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, Song E. Markers of tumor-initiating cells predict chemoresistance in breast cancer. PLoS One 2010, 5(12):e15630. 10.1371/journal.pone.0015630, 3004932, 21187973.
15. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69(8):3382-3389. 10.1158/0008-5472.CAN-08-4418, 2789401, 19336570.
16. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010, 363(20):1938-1948. 10.1056/NEJMra1001389, 21067385.
17. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer 2010, 102(2):369-375. 10.1038/sj.bjc.6605488, 2816658, 20010944.
18. Zhou L, Jiang Y, Yan T, Di G, Shen Z, Shao Z, Lu J. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res Treat 2010, 122(3):795-801. 10.1007/s10549-010-0999-4, 20571867.
19. van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, Falconer C, Smit VT, Kay C, van de Vijver MJ, Kuppen PJ, et al. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 2011, 125(3):671-685. 10.1007/s10549-010-0854-7, 20358279.
20. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007, 26(11):2389-2430. 10.1002/sim.2712, 17031868.
21. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 2005, 90(2):127-137. 10.1007/s10549-004-3777-3, 15803359.
22. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341(27):2061-2067. 10.1056/NEJM199912303412706, 10615079.
23. Anderson WF, Matsuno R. Breast cancer heterogeneity: a mixture of at least two main types?. J Natl Cancer Inst 2006, 98(14):948-951. 10.1093/jnci/djj295, 16849671.
24. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP, et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 2010, 20(4):440-446. 10.1101/gr.103606.109, 2847747, 20219944.
25. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011, 29(1):32-45. 10.1002/stem.563, 21280157.
26. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011, 10(9):1378-1384. 10.4161/cc.10.9.15486, 21552008.